Lisa Salberg and Dr. Marty Maron break down the rapidly changing landscape of HCM treatment, including the growing role of myosin inhibitors and what new clinical trial data could mean for patients. The conversation also explores beta blockers, shared care models, Centers of Excellence, and why personalized treatment matters more than ever.

This conversation was recorded May 8, 2026.